Pediatric Partial and Intermediate Atrioventricular Septal Defects Medication
- Author: M Silvana Horenstein, MD; Chief Editor: P Syamasundar Rao, MD more...
Medical treatment is indicated in patients with congestive heart failure (CHF) usually before surgical repair. However, it may also be needed in patients in whom mitral regurgitation (MR) persists postoperatively. The treatment outlined below is usually indicated for outpatient management.
Angiotensin-converting enzyme inhibitors (ACE inhibitors)
These medications are used to decrease the afterload to the left ventricle (LV) produced by the MR. This effect is achieved by producing peripheral vasodilatation, which, in turn, reduces systemic blood pressure (ie, reduces afterload). Reduction in systemic blood pressure decreases the amount of blood pumped by the LV with each systolic contraction (ie, stroke volume) and also reduces the pressure at which the blood is ejected. This, in turn, diminishes the amount of blood regurgitated by the mitral valve from the LV into the left atrium (LA) during systole, which decreases pulmonary venous pressure and, thus, decreases pulmonary congestion. By decreasing the afterload to the LV, ACE inhibitors reduce the left-to-right shunt through the atrioventricular septal defect (AVSD) or the atrial septal defect (ASD) in the case of partial AVSD.
A recently published observational study by Cooper et al reported that babies whose mothers had taken an ACE inhibitor during the first 3 months of pregnancy had an increased risk of birth defects compared with babies whose mothers had not taken any drugs for high blood pressure. At this time, based on this one observational study, the US Food and Drug Administration (FDA) did not change the pregnancy categories for ACE inhibitors. The current pregnancy categories assigned to ACE inhibitors are C for the first trimester and D for the second and third trimesters.
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in increased levels of plasma renin and a reduction in aldosterone secretion.
Helps control blood pressure and proteinuria. Decreases pulmonary-to-systemic flow ratio in the catheterization laboratory and increases systemic blood flow in patients with relatively low pulmonary vascular resistance. Has favorable clinical effect when administered over a long period. Helps prevent potassium loss in distal tubules. Body conserves potassium; thus, less oral potassium supplementation needed.
Patients who develop a cough, angioedema, bronchospasm, or other hypersensitivity reactions after starting ACE inhibitors should receive an angiotensin-receptor blocker.
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion. Rapidly absorbed, but bioavailability is significantly reduced with food intake. It achieves a peak concentration in an hour and has a short half-life. The drug is cleared by the kidney. Impaired renal function requires reduction of dosage. Absorbed well PO. Give at least 1 h before meals. If added to water, use within 15 min. Can be started at low dose and titrated upward as needed and as patient tolerates.
Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion.
These agents help decrease pulmonary congestion.
Loop diuretic that increases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending limb of loop of Henle and distal renal tubule. Increases renal blood flow without increasing filtration rate. Onset of action is generally within 1 h. Increases potassium, sodium, calcium, and magnesium excretion.
Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate with 1 mg/kg/dose increments until a satisfactory effect is achieved.
Diuretics have major clinical uses in managing disorders involving abnormal fluid retention (edema) or in treating hypertension, in which their diuretic action causes decreased blood volume. Chronic use of furosemide can lead to hypercalcemia with renal damage and electrolyte disturbances.
For management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions. Therefore, it is generally used when concomitant chronic use of sodium-wasting diuretics such as furosemide is noted.
It is used because of its direct inotropic effects in addition to indirect effects on the cardiovascular system.
Its indirect actions result in increased carotid sinus activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure. These effects help reduce the heart rate response to CHF, rendering a more effective stroke volume with each ventricular systole.
Enhances myocardial contractility by inhibition of Na+/K+ ATPase, a cell membrane enzyme that extrudes Na and brings K into the myocyte. Resulting increase in intracellular Na stimulates Na-Ca exchanger in the cell membrane, which extrudes Na and brings in Ca, leading to an increase in intracellular calcium in the sarcoplasmic reticulum of cardiac cells, therefore increasing contractility of myocyte (ie, positive inotropic effect). Has direct inotropic effects in addition to indirect effects on the cardiovascular system. Increases myocardial systolic contractions. It exerts vagomimetic action on sinus and AV nodes (slowing heart rate and conduction). Also, decreases degree of activation of sympathetic nervous system and renin-angiotensin system, which is referred to as the deactivating effect. May be given as a loading dose followed by a maintenance dose or simply as a maintenance regimen. Digitalis loading increases hazards of this drug. Therapeutic serum level range is 0.8-2 ng/mL.
Miller A, Siffel C, Lu C, Riehle-Colarusso T, Frias JL, Correa A. Long-term survival of infants with atrioventricular septal defects. J Pediatr. 2010 Jun. 156(6):994-1000. [Medline].
Briggs LE, Kakarla J, Wessels A. The pathogenesis of atrial and atrioventricular septal defects with special emphasis on the role of the dorsal mesenchymal protrusion. Differentiation. 2012 Jul. 84(1):117-30. [Medline]. [Full Text].
Guo Y, Shen J, Yuan L, Li F, Wang J, Sun K. Novel CRELD1 gene mutations in patients with atrioventricular septal defect. World J Pediatr. 2010 Nov. 6(4):348-52. [Medline].
Robinson SW, Morris CD, Goldmuntz E, Reller MD, Jones MA, Steiner RD, et al. Missense mutations in CRELD1 are associated with cardiac atrioventricular septal defects. Am J Hum Genet. 2003 Apr. 72(4):1047-52. [Medline]. [Full Text].
Inga A, Reamon-Buettner SM, Borlak J, Resnick MA. Functional dissection of sequence-specific NKX2-5 DNA binding domain mutations associated with human heart septation defects using a yeast-based system. Hum Mol Genet. 2005 Jul 15. 14(14):1965-75. [Medline].
Moskowitz IP, Wang J, Peterson MA, Pu WT, Mackinnon AC, Oxburgh L, et al. Transcription factor genes Smad4 and Gata4 cooperatively regulate cardiac valve development. [corrected]. Proc Natl Acad Sci U S A. 2011 Mar 8. 108(10):4006-11. [Medline]. [Full Text].
Tomita-Mitchell A, Mahnke DK, Struble CA, Tuffnell ME, Stamm KD, Hidestrand M, et al. Human gene copy number spectra analysis in congenital heart malformations. Physiol Genomics. 2012 May 1. 44(9):518-41. [Medline]. [Full Text].
Kutty S, Smallhorn JF. Evaluation of atrioventricular septal defects by three-dimensional echocardiography: benefits of navigating the third dimension. J Am Soc Echocardiogr. 2012 Sep. 25(9):932-44. [Medline].
Cheng HL, Huang CH, Tsai HE, Chen MY, Fan SZ, Hsiao PN. Intraoperative assessment of partial atrioventricular septal defect with a cleft mitral valve by real-time three-dimensional transesophageal echocardiography. Anesth Analg. 2012 Apr. 114(4):731-4. [Medline].
Prifti E, Bonacchi M, Bernabei M, et al. Repair of complete atrioventricular septal defects in patients weighing less than 5 kg. Ann Thorac Surg. 2004 May. 77(5):1717-26. [Medline].
Jacobs JP, O'Brien SM, Pasquali SK, Jacobs ML, Lacour-Gayet FG, Tchervenkov CI, et al. Variation in outcomes for benchmark operations: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database. Ann Thorac Surg. 2011 Dec. 92(6):2184-91; discussion 2191-2. [Medline]. [Full Text].
Kaza AK, Colan SD, Jaggers J, Lu M, Atz AM, Sleeper LA, et al. Surgical interventions for atrioventricular septal defect subtypes: the pediatric heart network experience. Ann Thorac Surg. 2011 Oct. 92(4):1468-75; discussion 1475. [Medline]. [Full Text].
Ten Harkel AD, Cromme-Dijkhuis AH, Heinerman BC, et al. Development of left atrioventricular valve regurgitation after correction of atrioventricular septal defect. Ann Thorac Surg. 2005 Feb. 79(2):607-12. [Medline].
Murashita T, Kubota T, Oba J, Aoki T, Matano J, Yasuda K. Left atrioventricular valve regurgitation after repair of incomplete atrioventricular septal defect. Ann Thorac Surg. 2004 Jun. 77(6):2157-62. [Medline].
Aeba R, Kudo M, Okamoto K, Yozu R. Bridging annuloplasty for left atrioventricular valve of partial atrioventricular septal defect. Ann Thorac Surg. 2012 May. 93(5):e137-9. [Medline].
Manning PB. Partial atrioventricular canal: pitfalls in technique. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2007. 42-6. [Medline].
Stulak JM, Burkhart HM, Dearani JA, Cetta F, Barnes RD, Connolly HM, et al. Reoperations after repair of partial atrioventricular septal defect: a 45-year single-center experience. Ann Thorac Surg. 2010 May. 89(5):1352-9. [Medline].
Abbruzzese PA, Napoleone A, Bini RM. Late left atrioventricular valve insufficiency after repair of partial atrioventricular septal defects: anatomical and surgical determinants. Ann Thorac Surg. 1990 Jan. 49(1):111-4. [Medline].
Aubert S, Henaine R, Raisky O, et al. Atypical forms of isolated partial atrioventricular septal defect increase the risk of initial valve replacement and reoperation. Eur J Cardiothorac Surg. 2005 Aug. 28(2):223-8. [Medline].
Najm HK, Williams WG, Chuaratanaphong S, Watzka SB, Coles JG, Freedom RM. Primum atrial septal defect in children: early results, risk factors, and freedom from reoperation. Ann Thorac Surg. 1998 Sep. 66(3):829-35. [Medline].
Jacobs JP, Jacobs ML, Mavroudis C, Chai PJ, Tchervenkov CI, Lacour-Gayet FG, et al. Atrioventricular septal defects: lessons learned about patterns of practice and outcomes from the congenital heart surgery database of the society of thoracic surgeons. World J Pediatr Congenit Heart Surg. 2010 Apr. 1(1):68-77. [Medline].
Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006 Jun 8. 354(23):2443-51. [Medline].
Allwork SP. Anatomical-embryological correlates in atrioventricular septal defect. Br Heart J. 1982 May. 47(5):419-29. [Medline].
Ebels T, Ho SY, Anderson RH, Meijboom EJ, Eijgelaar A. The surgical anatomy of the left ventricular outflow tract in atrioventricular septal defect. Ann Thorac Surg. 1986 May. 41(5):483-8. [Medline].
Ferencz C, Rubin JD, Loffredo CA, eds. The Epidemiology of Congenital Heart Disease, The Baltimore-Washington Infant Heart Study (1981-1989),. Perspectives in Pediatric Cardiology. Mount Kisco, NY: Futura Publishing Co; 1993. Vol 4:
Freeman SB, Taft LF, Dooley KJ, et al. Population-based study of congenital heart defects in Down syndrome. Am J Med Genet. 1998 Nov 16. 80(3):213-7. [Medline].
Jacobstein MD, Fletcher BD, Goldstein S, Riemenschneider TA. Evaluation of atrioventricular septal defect by magnetic resonance imaging. Am J Cardiol. 1985 Apr 15. 55(9):1158-61. [Medline].
LaCorte MA, Cooper RS, Kauffman SL, et al. Atrioventricular canal ventricular septal defect with cleft mitral valve. Angiographic and echocardiographic features. Pediatr Cardiol. 1982. 2(4):289-95. [Medline].
Lipshultz SE, Sanders SP, Mayer JE, Colan SD, Lock JE. Are routine preoperative cardiac catheterization and angiography necessary before repair of ostium primum atrial septal defect?. J Am Coll Cardiol. 1988 Feb. 11(2):373-8. [Medline].
Neufeld HN, Titus JL, Dushane JW, BUrchell HB, Edwards JE. Isolated ventricular septal defect of the persistent common atrioventricular canal type. Circulation. 1961 May. 23:685-96. [Medline].
Parsons JM, Baker EJ, Anderson RH, et al. Morphological evaluation of atrioventricular septal defects by magnetic resonance imaging. Br Heart J. 1990 Aug. 64(2):138-45. [Medline].
Piccoli GP, Gerlis LM, Wilkinson JL, et al. Morphology and classification of atrioventricular defects. Br Heart J. 1979 Dec. 42(6):621-32. [Medline].
Portman MA, Beder SD, Ankeney JL. A 20-year review of ostium primum defect repair in children. Am Heart J. 1985 Nov. 110(5):1054-8. [Medline].
Portman MA, Beder SD, Cohen MH, et al. Conduction abnormalities detected by electrophysiologic testing following repair of ostium primum atrioventricular septal defect. Int J Cardiol. 1986 Apr. 11(1):111-9. [Medline].
Pretre R, Dave H, Kadner A. Direct closure of the septum primum in atrioventricular canal defects. J Thorac Cardiovasc Surg. 2004 Jun. 127(6):1678-81.
Sadeghi AM, Laks H, Pearl JM. Primum atrial septal defect. Semin Thorac Cardiovasc Surg. 1997 Jan. 9(1):2-7. [Medline].
Singh A, Romp RL, Nanda NC, Rajdev S, Mehmood F, Baysan O, et al. Usefulness of live/real time three-dimensional transthoracic echocardiography in the assessment of atrioventricular septal defects. Echocardiography. 2006 Aug. 23(7):598-608. [Medline].
van den Bosch AE, van Dijk VF, McGhie JS, et al. Real-time transthoracic three-dimensional echocardiography provides additional information of left-sided AV valve morphology after AVSD repair. Int J Cardiol. 2006 Jan 26. 106(3):360-4. [Medline].
Wang ZJ, Reddy GP, Gotway MB, et al. Cardiovascular shunts: MR imaging evaluation. Radiographics. 2003 Oct. 23 Spec No:S181-94. [Medline].